Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 16/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.79 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.79 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | LYN | P07948 | 1/20 | 0.79 |
| ▸ | PRKACA | P17612 | 1/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.79 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.79 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.79 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.79 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.79 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.79 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.79 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931274 | 1.00 | PRKCI (0.79) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL6931267 | 1.00 | PRKCI (0.79) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| Hydrochloric Acid SCHEMBL6934785 | 0.99 | PRKCI (0.77) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| Hydrochloric Acid SCHEMBL6934793 | 0.99 | PRKCI (0.77) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| Hydrochloric Acid SCHEMBL6934791 | 0.99 | PRKCI (0.77) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL6934167 | 0.96 | PRKCI (0.72) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL6934165 | 0.96 | PRKCI (0.72) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL8328726 | 0.92 | PRKCI (0.68) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL27526011 | 0.92 | MAPK9 (0.82) | PRKCIMAPK14MAPK9MAPK13MAP4K4 | |
| SCHEMBL6929767 | 0.92 | MAPK9 (0.82) | PRKCIMAPK14MAPK9MAPK13MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | claimed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | claimed |
| CN-1328277-C | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | PRKCI 3097/4885MAPK14 2062/4885MAPK9 1576/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | PRKCI 3717/4885MAPK14 1169/4885MAPK9 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.